Scientists create miniature human heart model in the lab

NewsGuard 100/100 Score

Cardiovascular-related disorders are a significant global health problem. Cardiovascular disease (CVD) is the leading cause of death in developed countries, accounting for a third of the mortality rate in the United States alone. At the same time, congenital heart defects (CHD) affect less than 1 percent of newborns, making it the most common congenital disabilities in humans.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Studying cardiovascular disorders is a common problem among scientists, but now, a team of researchers from Michigan State University has created a miniature human heart model in the laboratory. For the first time in history, this mode is complete with all primary heart cell types and a functioning structure of chambers and vascular tissue.

“Here, we report the most faithful in vitro organoid model of human cardiovascular development to date using human pluripotent stem cells (hPSCs). Our protocol is highly efficient, scalable, shows high reproducibility, and is compatible with high-throughput approaches,” the researchers wrote in the paper.

The scientists believe that their model can enable them to study all kinds of cardiac disorders more accurately than before.

Appearing on the preprint server bioRxiv*, the study was funded by grants from the American Heart Association and the National Institutes of Health.

Human heart organoids (hHO)

Research on stem cells and developmental biology has made it possible to grow small pieces of tissue in the laboratory called organoids. Organoids closely resemble many organs, from the liver and brain to the kidneys.

Getting human tissue to study is difficult to obtain, but organoids provide scientists with new alternatives to study human organs and disease. They can use organoids to study the complex interactions of cells, which is not possible with other experimental models.

Human heart organoids (hHOs) are mini hearts that constitute powerful models to study all kinds of cardiac disorders. The hHOs were created by a novel stem cell framework that is based on the embryonic and fetal developmental environments.

“This process allows the stem cells to develop, basically as they would in an embryo, into the various cell types and structures present in the heart. We give the cells the instructions, and they know what they have to do when all the appropriate conditions are met,” Aitor Aguirre, the study’s senior author and assistant professor of biomedical engineering at MSU’s Institute for Quantitative Health Science and Engineering, said.

These organoids are self-assembling 3D constructs that mimic organ properties and structures, allowing scientists to study heart diseases more efficiently and more accurately at the cellular level.

“The hHOs allow higher-order interaction of distinct heart tissues for the first time and display biologically relevant physical and topographical 3D cues that closely resemble the human fetal heart. Our model constitutes a powerful novel tool for discovery and translational studies in human cardiac development and disease,” the team wrote in the paper.

Real-time analysis and observation

Further, since the organoids developed following natural cardiac embryonic development, the researchers were able to study the natural growth of an actual fetal human heart in real-time. This allows them to learn more about the heart’s structure and function.

One of the hurdles experienced by scientists in studying congenital heart defects is access to a developing heart. In the past, they study fetal heart development with the use of animal models or donated fetal remains. Now, with a mini heart that they can observe from the start of its development, it can provide more accurate information on how congenital heart defects emerge.

“Now, we can have the best of both worlds, a precise human model to study these diseases — a tiny human heart — without using fetal material or violating ethical principles. This constitutes a great step forward,” Aguirre said.

“In the lab, we are currently using heart organoids to model congenital heart disease — the most common congenital disability in humans affecting nearly 1% of the newborn population. With our heart organoids, we can study the origin of congenital heart disease and find ways to stop it,” he added.

Future plans

For the research team, the study is just the first of the many experiments they will make. While their model is complex, it is far from perfect. The team plans on improving the organoid to provide a better version for future research and use.

The team said that the mini heart is not as perfect as the human heart, but they are working on it. Also, the team hopes for a broad range of applicability of the miniature hearts, enabling them to study other cardiovascular-related diseases, including chemotherapy-induced cardiotoxicity and the effects of diabetes on the developing fetal heart during pregnancy.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Source:
Journal references:

Article Revisions

  • Mar 24 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Angela Betsaida B. Laguipo

Written by

Angela Betsaida B. Laguipo

Angela is a nurse by profession and a writer by heart. She graduated with honors (Cum Laude) for her Bachelor of Nursing degree at the University of Baguio, Philippines. She is currently completing her Master's Degree where she specialized in Maternal and Child Nursing and worked as a clinical instructor and educator in the School of Nursing at the University of Baguio.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Laguipo, Angela. (2023, March 24). Scientists create miniature human heart model in the lab. News-Medical. Retrieved on May 09, 2024 from https://www.news-medical.net/news/20200819/Scientists-create-miniature-human-heart-model-in-the-lab.aspx.

  • MLA

    Laguipo, Angela. "Scientists create miniature human heart model in the lab". News-Medical. 09 May 2024. <https://www.news-medical.net/news/20200819/Scientists-create-miniature-human-heart-model-in-the-lab.aspx>.

  • Chicago

    Laguipo, Angela. "Scientists create miniature human heart model in the lab". News-Medical. https://www.news-medical.net/news/20200819/Scientists-create-miniature-human-heart-model-in-the-lab.aspx. (accessed May 09, 2024).

  • Harvard

    Laguipo, Angela. 2023. Scientists create miniature human heart model in the lab. News-Medical, viewed 09 May 2024, https://www.news-medical.net/news/20200819/Scientists-create-miniature-human-heart-model-in-the-lab.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
MedStar Washington Hospital Center enrolls first U.S. patient in gene-editing therapy trial for heart disease